Digital Library
Close Browse articles from a journal
 
<< previous    next >>
     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
           All articles of the corresponding issues
                                       Details for article 5 of 9 found articles
 
 
  Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
 
 
Title: Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048
Author: Semrad, Thomas J
Groshen, Susan
Luo, Chunqiao
Pal, Sumanta
Vaishampayan, Ulka
Joshi, Monika
Quinn, David I.
Mack, Philip C.
Gandara, David R.
Lara, Primo N.
Appeared in: Kidney cancer
Paging: Volume 3 (2019) nr. 1 pages 51-61
Year: 2019-02-05
Contents:
Publisher: IOS Press, Amsterdam
Source file: Elektronische Wetenschappelijke Tijdschriften
 
 

                             Details for article 5 of 9 found articles
 
<< previous    next >>
 
 Koninklijke Bibliotheek - National Library of the Netherlands